CSL Ltd (ASX: CSL) is one of those rare Australian stocks that truly deserves a place in the buy and hold forever basket.
Yet right now, more investors are hitting the sell button than the buy rating.
As a result, the market is giving investors the opportunity to pick up shares in the biotechnology giant at a sizeable discount.
In fact, CSL shares last traded at $215.71, which is 30% lower than their 52-week high of $310.00.
Image source: Getty Images
A quality opportunity
Periods of volatility often rattle investors, but they also present opportunities.
Buying high-quality ASX stocks when they are temporarily out of favour has historically been one of the best ways to generate long-term wealth.
CSL is a textbook example of quality. It is a global biotechnology leader with an extraordinary track record of growth, innovation, and capital allocation. Its plasma therapies and vaccine operations are entrenched in markets that have high barriers to entry and consistent demand.
Importantly, for long-term investors, nothing fundamental about CSL's competitive advantages has changed just because its share price has slid.
What has spooked the market?
ASX stocks don't crash for no reason, so what is going on here?
The sell-off this month followed CSL's FY 2025 results and news of a major transformation program. Management announced the closure of underperforming US plasma centres, a sizeable headcount reduction, and a restructuring charge for FY 2026. While these moves are designed to boost efficiency and margins over time, they spooked the market in the short term.
There were also revenue misses in parts of CSL Behring and Seqirus, with vaccination uptake in the US softer than expected. These nearer-term headwinds have weighed on sentiment. But importantly, CSL still grew its profits by double digits and lifted its final dividend.
Why the long-term story remains intact
History shows that CSL has navigated many cycles before and continued to grow strongly.
Its therapies are essential, demand for plasma products continues to expand, and its R&D pipeline positions it well for the future. Cost savings from the transformation plan are expected to deliver hundreds of millions in annualised benefits by FY 2028, setting the company up for a stronger margin profile.
On top of this, CSL plans to demerge Seqirus as a standalone vaccines leader and restart on-market buybacks. These are signs of confidence in its long-term growth and capital management discipline.
Should you buy this ASX stock?
The team at Macquarie thinks this is a buying opportunity for investors.
It remains very upbeat on CSL's outlook and has put an outperform rating and a $295.90 price target on its shares. Based on its current price of $215.71, this implies potential upside of close to 37%.
In light of this, the market's pessimism may have created a compelling entry point into one of the ASX's highest-quality businesses.
